Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.
A novel injectable cephalosporin, E1040, significantly eradicated Pseudomonas aeruginosa from the urine, in contrast to ceftazidime, in rats with complicated P. aeruginosa urinary tract infections associated with urinary stones, suggesting that E1040 is a prospective therapeutic agent in the management of refractory Pseudomonas urinary tract infections.
Satoh
M
M
Department of Microbiology, Tokyo Research Laboratories, Eisai Co., Ltd., Japan.
Munakata
K
K
Takeuchi
H
H
Yoshida
O
O
D000818:Animals; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007273:Injections, Intramuscular; D011512:Proteus Infections / Q000150:complications / Q000188:drug therapy*; D011513:Proteus mirabilis / Q000187:drug effects / Q000302:isolation & purification; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D051381:Rats; D011919:Rats, Inbred Strains; D014545:Urinary Calculi / Q000150:complications / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy*
D002511:Cephalosporins; C056494:cefclidin; D002442:Ceftazidime